Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

siponimod

Novartis changes executive committee

Robert Welteverden is appointed head of Novartis Business Services

- PMLiVE

Real-world data finds patients feel better on Entresto, says Novartis

Patients on Entresto reported an “early, statistically significant improvement in health status”

- PMLiVE

Novartis, Amgen set low price for first CGRP migraine drug

Aimovig has a list price of $6,900 per year

- PMLiVE

Novartis legal head resigns over Cohen payments

General counsel steps down, but Novartis still facing difficult questions

- PMLiVE

Daily Brief

A rapid round-up of the top pharma, biotech and healthcare news

Sanofi reception

Sanofi’s latecomer PD-1 gets date for FDA verdict

While Keytruda extends its lead, Sanofi makes a late bid to enter PD-1 space

- PMLiVE

Novartis launches remote clinical trial app

FocalView will allow patients to participate in ophthalmology trials

- PMLiVE

Rigel and Ultragenyx claim approvals for rare drugs

Tavalisse and Crysvita are set to treat patients with chronic ITP and XLH, respectively

- PMLiVE

Amgen and Novartis migraine drug hits the mark again

Aimovig will become the first CGRP receptor-targeting drug if it reaches market

Bristol-Myers Squibb (BMS) building

BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer

Data shows the combo can improve survival compared to Pfizer’s Sutent

Brexit Means Brexit

The differential destinations of post-Brexit pharma

- PMLiVE

Novartis buys gene therapy firm AveXis for $8.7bn

Lead candidate AVXS-101 could potentially replace regular drug treatment for SMA with a one-off intervention

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links